Zydus Lifesciences has informed that it enclosed a copy of press release dated December 11, 2023 titled ‘Zydus and Daewoong Pharmaceutical announce exclusive licensing agreement for development and commercialization of Leuprolide Long-Acting Injectable in the U.S’.
The above information is a part of company’s filings submitted to BSE.